CA2770915C - Use of mycobacterium bovis bcg killed by extended freeze drying (efd) for preventing or treating atherosclerosis - Google Patents

Use of mycobacterium bovis bcg killed by extended freeze drying (efd) for preventing or treating atherosclerosis Download PDF

Info

Publication number
CA2770915C
CA2770915C CA2770915A CA2770915A CA2770915C CA 2770915 C CA2770915 C CA 2770915C CA 2770915 A CA2770915 A CA 2770915A CA 2770915 A CA2770915 A CA 2770915A CA 2770915 C CA2770915 C CA 2770915C
Authority
CA
Canada
Prior art keywords
efd
mice
mycobacterium bovis
bovis bcg
bcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2770915A
Other languages
English (en)
French (fr)
Other versions
CA2770915A1 (en
Inventor
Gilles Marchal
Micheline Lagranderie
Isabelle Schwartz-Cornil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de Recherche pour lAgriculture lAlimentation et lEnvironnement
Institut Pasteur
Original Assignee
Institut National de la Recherche Agronomique INRA
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique INRA, Institut Pasteur filed Critical Institut National de la Recherche Agronomique INRA
Publication of CA2770915A1 publication Critical patent/CA2770915A1/en
Application granted granted Critical
Publication of CA2770915C publication Critical patent/CA2770915C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2770915A 2009-08-13 2010-08-12 Use of mycobacterium bovis bcg killed by extended freeze drying (efd) for preventing or treating atherosclerosis Expired - Fee Related CA2770915C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290627A EP2292260A1 (en) 2009-08-13 2009-08-13 Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
EP09290627.0 2009-08-13
PCT/IB2010/053652 WO2011018769A1 (en) 2009-08-13 2010-08-12 Use of mycobacterium bovis bcg killed by extended freeze drying (efd) for preventing or treating atherosclerosis

Publications (2)

Publication Number Publication Date
CA2770915A1 CA2770915A1 (en) 2011-02-17
CA2770915C true CA2770915C (en) 2017-12-05

Family

ID=41402542

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2770915A Expired - Fee Related CA2770915C (en) 2009-08-13 2010-08-12 Use of mycobacterium bovis bcg killed by extended freeze drying (efd) for preventing or treating atherosclerosis

Country Status (7)

Country Link
US (1) US8414865B2 (enExample)
EP (2) EP2292260A1 (enExample)
JP (1) JP5762407B2 (enExample)
CA (1) CA2770915C (enExample)
DK (1) DK2464378T3 (enExample)
ES (1) ES2563577T3 (enExample)
WO (1) WO2011018769A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013106785B4 (de) 2013-06-28 2018-11-29 Pilz Auslandsbeteiligungen Gmbh Verfahren zur Synchronisation eines Lichtgitters und auf diesem Verfahren beruhendes Lichtgitter
CN105829885B (zh) 2013-10-17 2020-08-18 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
JP6628071B2 (ja) * 2015-04-28 2020-01-08 国立大学法人北海道大学 低密度リポタンパク質酸化抑制剤
US11266730B2 (en) * 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
EP3890759B1 (en) 2018-12-04 2023-08-23 Sabiotec Spin-Off, S.L. Immunostimulant for use against pathogens
WO2024180083A1 (en) * 2023-02-27 2024-09-06 Westfälische Wilhelms-Universität Münster Oral vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US6350457B1 (en) * 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
CA2469334C (en) 2001-12-11 2012-05-08 Institut Pasteur Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
CA2531261A1 (en) 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
EP1916000A1 (en) * 2006-10-26 2008-04-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of measles virus nucleoprotein for treating atherosclerosis
EP2087898A1 (en) * 2008-02-06 2009-08-12 Institut Pasteur A preparation of mycobacterium bovis BCG killed by extended freeze drying (EFD) for treating rheumatoid arthritis

Also Published As

Publication number Publication date
CA2770915A1 (en) 2011-02-17
JP2013501775A (ja) 2013-01-17
US20120201856A1 (en) 2012-08-09
EP2292260A1 (en) 2011-03-09
US8414865B2 (en) 2013-04-09
EP2464378B1 (en) 2015-11-11
DK2464378T3 (en) 2016-02-08
WO2011018769A1 (en) 2011-02-17
EP2464378A1 (en) 2012-06-20
ES2563577T3 (es) 2016-03-15
JP5762407B2 (ja) 2015-08-12

Similar Documents

Publication Publication Date Title
CA2770915C (en) Use of mycobacterium bovis bcg killed by extended freeze drying (efd) for preventing or treating atherosclerosis
Smits et al. Protective effect of Schistosoma mansoni infection on allergic airway inflammation depends on the intensity and chronicity of infection
Bach et al. The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes
Persson et al. Mycobacterium tuberculosis-induced apoptotic neutrophils trigger a pro-inflammatory response in macrophages through release of heat shock protein 72, acting in synergy with the bacteria
JP2018524393A (ja) 免疫応答を誘導するための新規方法
Ovchinnikova et al. Mycobacterium bovis BCG killed by extended freeze‐drying induces an immunoregulatory profile and protects against atherosclerosis
AU2012331646B2 (en) Effect of an attenuated Bordetella strain against allergic disease
Deslyper et al. The role of the liver in the migration of parasites of global significance
AU2014213631B2 (en) Phosphorylcholine conjugates and uses thereof
Ueno et al. A dendritic cell-based systemic vaccine induces long-lived lung-resident memory Th17 cells and ameliorates pulmonary mycosis
Qu et al. L-theanine modulates intestine-specific immunity by regulating the differentiation of CD4+ T cells in ovalbumin-sensitized mice
Silvane et al. A vaccine based on Kunitz-type molecule confers protection against Fasciola hepatica challenge by inducing IFN-γ and antibody immune responses through IL-17A production
Taguchi et al. Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner
Peres et al. Previous contact with Strongyloides venezuelensis contributed to prevent insulitis in MLD-STZ diabetes
CN108697784B (zh) 用于对屋尘螨来源的过敏原的超敏反应的免疫调节剂
RU2473365C1 (ru) Вакцина mycobacterium tuberculosis
Rao et al. Mycobacterium tuberculosis proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model
KR20020021375A (ko) 미코박테리움 바카이를 활용하여 면역적으로 매개된질병을 치료하는 방법 및 조성물
CN101384270A (zh) 用灭活的或非感染性的细菌制备物控制肠道炎症综合征
Bermudez-Fajardo et al. The effect of Chlamydophila pneumoniae Major Outer Membrane Protein (MOMP) on macrophage and T cell-mediated immune responses
US20130011437A1 (en) Immune compositions for treating H. pylori infection
Bau Deciphering the early events leading to an adaptive immune response during urinary tract infection
Shin et al. Regulatory effect of Scutellariae radix on the proinflammatory cytokine production and abnormal T-cell activation in vitro in pristane-induced lupus mice
van Puijvelde et al. The effect of NKT cell activation on atherosclerosis depends on apoE and lipid loading
van Dijk et al. Loss of ex-vivo muscle function with preserved muscle mass in middle aged mice seems a sensitive indicator for the onset of sarcopenia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150721

MKLA Lapsed

Effective date: 20220812